Last Price
105.81
Today's Change
+3.18 (3.09%)
Day's Change
102.62 - 107.35
Trading Volume
305,719
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. James R. Porter Ph.D. Dr. James R. Porter Ph.D.
Full Time Employees: 115 115
IPO Date: 2021-07-29 2021-07-29
CIK: 0001861560 0001861560
ISIN: US6707031075 US6707031075
CUSIP: 670703107 670703107
Beta: 1.28 1.28
Last Dividend: 0.00 0.00
Dcf Diff: 96.87 96.87
Dcf: 5.76 5.76
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.